These companies reported tough numbers this past quarter. Here's why this may be a great opportunity.
Does this analyst make a good case or is it just more noise from Wall Street?
Merck has a slight earnings miss, but announces some very exciting partnerships.
Fourth-quarter results were a mixed bag for Bristol-Myers Squibb (NYSE: BMY). Can it perform in 2014?
Who will win the high-stakes immuno-oncology race?
Friday's health-care winners and losers.
Two tech companies with wildly different focuses and one health-care mainstay end as the worst performers in the stock market today
Strong international sales and oncology division growth, couple with tight cost controls and a renewed focus on specialized care pushes Bristol-Myers Squibb's fourth-quarter results higher.
Why Procter & Gamble, Honeywell, and Bristol-Myers Squibb stocks are on the move today.
Bristol-Myers Squibb stock has hit decade highs lately, with promising drug candidates inspiring investors to greater confidence. But will Bristol-Myers Squibb earnings follow suit? Find out here.